The TRAVERSE Study: Evaluating Testosterone Therapy in Hypogonadal Men
The TRAVERSE (Therapy for Assessment of long-term Vascular events and Efficacy Response in hypogonadal men) study is a significant milestone in understanding the safety
November 4, 2024